Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis
R. Nakov, T. Velikova, V. Nakov, G. Ianiro, V. Gerova, L. Tankova Clinic of Gastroenterology, “Tsaritsa Yoanna – ISUL” University Hospital, Medical University of Sofia, Sofia, Bulgaria. radislav.nakov@gmail.com
OBJECTIVE: In this study, we aimed to evaluate the role of serum trefoil factor 3 (TFF3) as a biomarker of disease activity in patients with inflammatory bowel disease (IBD) and to compare TFF3 values with those of fecal calprotectin (FC).
PATIENTS AND METHODS: 128 patients with IBD were divided into four groups: 1) active ulcerative colitis (UC); 2) quiescent UC; 3) active Crohn’s disease (CD); 4) quiescent CD. The serum levels of TFF3 and FC levels were assessed in all patients and 16 controls.
RESULTS: Patients with active UC had higher TFF3 levels than those with quiescent UC (p<0.001), those with active (p<0.001) or quiescent CD (p<0.001) and controls (p <0.001). We found a correlation between TFF3 and FC values in patients with active (r = 0.478, p = 0.006) and quiescent UC (r=0.528, p=0.002). TFF3 levels correlated with endoscopic activity in UC (evaluated by UC Endoscopic Index of Severity – UCEIS) (r=0.662, p<0.001).
CONCLUSIONS: Serum TFF3 is able to identify patients with active UC. It could be used as a marker to predict disease activity in patients with UC.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
R. Nakov, T. Velikova, V. Nakov, G. Ianiro, V. Gerova, L. Tankova
Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis
Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 2
Pages: 788-794
DOI: 10.26355/eurrev_201901_16893